Skip to content
Parakho

Lincoln Pharmaceuticals Ltd

NSE LINCOLNBSE 531633

Q1 FY27, unaudited

Revenue
₹177.28 Cr
Profit after tax
₹36.23 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations177.28+15.07%671.03
Other income24.26+58.89%33.45
Total income201.55+19.02%704.48
Employee benefit expense33.31+4.89%125.19
Finance costs0.26+23.31%1.01
Depreciation & amortisation3.88+11.71%14.50
Total expenses153.99+14.96%588.86
Profit before tax47.55+34.37%115.63
Tax expense11.32+46.74%27.73
Profit after tax36.23+30.93%87.89
Total comprehensive income36.65+32.33%89.57
Earnings per share
Earnings per share, basic₹18.09₹43.88
Earnings per share, diluted₹18.09₹43.88

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Lincoln Pharmaceuticals Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 17 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 14 Aug 2026.